{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:04:49Z","timestamp":1768097089141,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jaad.2006.08.067","type":"journal-article","created":{"date-parts":[[2006,11,8]],"date-time":"2006-11-08T07:30:00Z","timestamp":1162971000000},"page":"580-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1016","volume":"56","author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.08.067_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0268-960X(03)00004-3","article-title":"Primary cutaneous lymphomas: a review with current treatment options","volume":"17","author":"Querfeld","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaad.2006.08.067_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CDLI.6.1.79-84.1999","article-title":"Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T-cells of patients with cutaneous T-cell lymphoma","volume":"6","author":"Lee","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jaad.2006.08.067_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by S\u00e9zary syndrome patients: cytokine secretion pattern resembles murine Th2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.08.067_bib4","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","article-title":"CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior","volume":"19","author":"Vermeer","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2006.08.067_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cyto.990190409","article-title":"Phenotype transition of CD4+ T-cells from CD45RA to CD45RO is accompanied by cell activation and proliferation","volume":"19","author":"Johannison","year":"1995","journal-title":"Cytometry"},{"key":"10.1016\/j.jaad.2006.08.067_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-3083.2000.00644.x","article-title":"Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood","volume":"51","author":"Hodge","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaad.2006.08.067_bib7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jaad.2006.08.067_bib8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2006.08.067_bib9","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2006.08.067_bib10","first-page":"204","article-title":"Cytokine-based therapy for melanoma: pre-clinical studies","volume":"10","author":"Shurin","year":"2000","journal-title":"Forum (Genova)"},{"issue":"Suppl","key":"10.1016\/j.jaad.2006.08.067_bib11","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"issue":"Suppl","key":"10.1016\/j.jaad.2006.08.067_bib12","first-page":"S93","article-title":"Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe","volume":"6","author":"Negrier","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.jaad.2006.08.067_bib13","first-page":"504","article-title":"A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2)","volume":"68","author":"Nagatani","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.08.067_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2133.1992.tb14832.x","article-title":"Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma","volume":"127","author":"Rybojad","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.08.067_bib15","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V83.8.2081.2081","article-title":"Interleukin-2 treatment in lymphoma: a phase II multicenter study","volume":"83","author":"Gisselbrecht","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2006.08.067_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.1995.01690170076011","article-title":"High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma","volume":"131","author":"Marolleau","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.08.067_bib17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archderm.1997.03890410120021","article-title":"Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2","volume":"133","author":"Baccard","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.08.067_bib18","first-page":"191b","article-title":"Phase I trial subcutaneous outpatient interleukin-2 for patients with advanced mycosis fungoides","volume":"88","author":"Gold","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2006.08.067_bib19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.0022-202X.2005.23914.x","article-title":"Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in S\u00e9zary syndrome patients","volume":"125","author":"Bouaziz","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.08.067_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00002371-200309000-00002","article-title":"Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy","volume":"26","author":"Fumagalli","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2006.08.067_bib21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1172\/JCI19441","article-title":"Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25\u2013 T\u00a0cells","volume":"112","author":"Walker","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2006.08.067_bib22","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by\u00a0naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206025199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206025199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:04Z","timestamp":1759269964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206025199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0190962206025199"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.08.067","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and S\u00e9zary syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.08.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}